Teniposide and cytarabine combination chemotherapy in the treatment of relapsed adolescent and adult acute lymphoblastic leukemia
Sanz, G.F.; Sanz, M.A.; Rafecas, F.J.; Martínez, J.A.; Martín-Aragonés, G.; Marty, M.L.
Cancer Treatment Reports 70(11): 1321-1323
1986
ISSN/ISBN: 0361-5960 PMID: 3464352 Document Number: 283736
Nineteen adolescents and adults with relapsed acute lymphoblastic leukemia (ALL) were treated with teniposide (VM-26) plus cytarabine (ara-C). Eight patients (42%) achieved complete remission. Infection and bleeding secondary to myelosuppression were the most serious complications seen. Responders received periodic reinductions with VM-26 and ara-C, but all relapsed within 16 weeks from remission. Our data demonstrate the effectiveness of combination chemotherapy with VM-26 plus ara-C in adolescent and adult ALL in relapse and suggest testing of this combination in first-line protocols. For remission maintenance, the association of other drug combinations is necessary.